VMC is aedsaiostc twhi eignticfn gnrao narstalptn .tsietanp CMV si rmstttnedia vai esxual aotncc,t roagn lnstpra,ant ro llicvatyer via pn.acltae aotcteiRvani of CVM orscuc ni het snsoe.emupdprmsiu
Ogrna nlaattrpsn apntitse era ta an eacriedns riks of CVM e.mnnpoaui
eh asw neerv iegnv avigronlcic - i used ahtt as a lcue vore snptrtaanl jreieotcn
hyW odwul isht ont eb tucea nasattlnrp eorjtneci nieladg to ?DRSA The riennictea is leete,vad dan I see ayn rosane yhw it lowud eb tleeaedv beyond cjetoreni
via @sammyj98 via UpToDate:
Universal prophylaxis with valganciclovir or ganciclovir is typically given to patients at risk for cytomegalovirus (CMV) reactivation (eg, seropositive recipients and those with seropositive donors). The duration of therapy often depends on the type of organ transplanted, the risk status of the patient, and individual institutional practice. Some transplant centers prefer to use a pre-emptive approach (eg, routine CMV viral load monitoring within initiation of treatment when reactivation becomes evident) for specific patient populations.
submitted by ∗amorah(115)
It can be re-accessed by making a purchase.
Purchase your membership here
$279$49evFre ;t-g& lrue otu ltef trearnivucl ruiafel M- MTXSP hpyrlxaiosp ;-tg& lure tou ycsunsometiP jKyinorcevidei napratnstl ubt on RBCBW/C in irneu tg-&; elur uot arntpastln eeontjrci
aiLnveg VMC and palyatci betumcyimaorc sa eth mnrngiiea otw ionps.to CVM si mero lykeli ni a tnplatrasn ntitae.p
$279$49